Foster Coulson

Entrepreneur | The Wellness Group

[The Wellness Company @twc_health]

Shop our biggest sale of the year to celebrate Americas 250th Birthday!

https://t.co/XKlKJlumQQ

[The Wellness Company @twc_health]

🇺🇸 250 Years of Freedom — celebrate right!​

💥 20% OFF sitewide, still going strong​
🚑 Medical Kits​
🧬 Supplements​
👨‍⚕️ Physician-Guided Rx​
⏰ Plus, get a free Anti-Aging Face Serum with any order

— Limited Supply — Shop now.

[The Wellness Company @twc_health]

🇺🇸 4th of July Savings are our biggest of the year!!​

🎆 Save 20% sitewide​
🚑 Medical Kits​
🧬 Supplements​
👨‍⚕️ Physician-Guided Rx​
🔥 Sale runs through Sunday — shop now

https://t.co/XKlKJltP1i

[Peter A. McCullough, MD, MPH® @P_McCulloughMD]

BREAKING--Clinical Effectiveness of Wellness Company Emergency Medical Kits

Overwhelming impact. Enabling users to self-manage and avoid burdening the healthcare system. @twc_health @NicHulscher @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson https://t.co/ENdnHQnOAk

[Nicolas Hulscher, MPH @NicHulscher]

BREAKING: First-Ever Real-World Study of Emergency Medication Kits Finds 86.1% Avoided Hospital, Urgent Care, or Clinic Visitation

Across 367 real-world illness episodes (respiratory, urinary, gastrointestinal, dental, and skin conditions):

- 81.6% reported meaningful improvement within 3 days
- 36.7% reported improvement within 24 hours
- 86.1% avoided hospital, urgent care, or clinic visitation
- 51.8% felt reduced need to go to urgent care or ER
- 95.8% reported overall benefit
- Side effects occurred in just 2.4% and were all mild

Pre-prescribed emergency medication kits have grown in popularity in recent years, yet no real-world utilization data on this product category had ever been published.

To address this evidence gap, we conducted the first real-world study evaluating how pre-prescribed emergency medication kits are actually used, for what conditions, with what outcomes, and with what safety profile.

The results suggest that they are associated with rapid symptom improvement and represent a practical model for improving timely access to treatment of common acute illnesses when conventional healthcare access is limited, delayed, or inconvenient.

@twc_health @P_McCulloughMD @DrKellyVictory @jathorpmfm @DrHarveyRisch @drdrew @FosterCoulson @PeterGillooly

[Nicolas Hulscher, MPH @NicHulscher]

BREAKING: Our peer-reviewed ivermectin + mebendazole cancer study showing 84.4% clinical benefit just became the #1 RESULT ON GOOGLE

The world is waking up to the ENORMOUS potential of anti-parasitics for cancer.

The Chemo Cartel is panicking.

[The Wellness Company @twc_health]

BREAKING: Our peer-reviewed ivermectin + mebendazole cancer study showing 84.4% clinical benefit just became the #1 RESULT ON GOOGLE

Access the study here 👇
https://t.co/CTjEXmbZf9

[The Wellness Company @twc_health]

PUBLISHED!

🔗 https://t.co/CTjEXmbZf9

[Nicolas Hulscher, MPH @NicHulscher]

BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal

84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.

Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.

The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.

Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.

At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)

Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.

Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.

This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.

With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.

In the meantime, many cancer patients are exercising their right to try.

@twc_health @McCulloughFund @IIAR_Journals @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson

[The Wellness Company @twc_health]

From “I want an open debate” to a temper tantrum in 30 seconds.

Nothing derails a good argument faster than someone getting hit with a logical point they can’t answer — then suddenly switching gears, playing the victim card, and trying to make the conversation about anything except the argument.

That’s not debate. That’s deflection.

[The Wellness Company @twc_health]

We are proud to announce the publication of “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients” in Anticancer Research, a respected international peer-reviewed oncology journal. 

The study evaluated 197 cancer patients across multiple diagnoses — making it one of the largest peer-reviewed human studies to date examining the adjunctive use of IVM + MEB in cancer care.

The findings were significant!

Access the study link in the comments below 👇

@P_McCulloughMD @NicHulscher @DrKellyVictory @drdrew @jathorpmfm @alejandrodiazmd @PeterGillooly

[Peter A. McCullough, MD, MPH® @P_McCulloughMD]

Emergency Room Trips Abroad Can be Avoided

Don't start your tip without a Wellness Company Emergency Medical Kit. Courtesy Ansley Earhardt, Fox and Friends @ainsleyearhardt @foxandfriends @FoxNews @twc_health https://t.co/xohvEsMIEi

[Peter A. McCullough, MD, MPH® @P_McCulloughMD]

Emergency Medical Kits Essential for Travel Season

Cruise ship outbreaks, Lyme disease escalating, so many reasons to be prepared. Courtesy Ainsley Earhardt, Fox and Friends. @ainsleyearhardt @foxandfriends @VigilantFox @twc_health

[Peter A. McCullough, MD, MPH® @P_McCulloughMD]

Wellness Company Sparking Clinical and Research Interest in IVM-Meb

Courtesy Newsmax American Agenda @NEWSMAX @twc_health https://t.co/sl7P1sSvud

[The Wellness Company @twc_health]

If 90% goes to treatment, what goes to prevention? Less than 3% of total U.S. health spend.

The 5 leading causes of death in the U.S. are all chronic diseases — and 4 of them are largely preventable.

"We've built a system that profits when you fail to stay well." The math above is the receipt.

[Peter A. McCullough, MD, MPH® @P_McCulloughMD]

Big Apple Exclusive: Dr. McCullough Goes Live to Unveil Potential Cancer Breakthrough

Dr. McCullough arrives in New York demanding the National Cancer Institute fulfill its obligation to test ivermectin and mebendazole against cancer @BobBrooks_NMX @KatrinaSzish @twc_health https://t.co/hBKhe2CW4W

[Peter A. McCullough, MD, MPH® @P_McCulloughMD]

WHO Blunder Imperils Remaining Passengers on Hantavirus-Infected Cruise Ship

Locked-down in cabins, HVAC system not sterilized from rodent excrement dust carrying virions, passengers are sitting ducks for fatal illness @McCulloughFund @WHO @RealAmVoice @twc_health https://t.co/TV45VyuYRS

[McCullough Foundation @McCulloughFund]

Not All Cancers Are the Same. The Right Drug Combination Needs to Be Tested Across All of Them.

Prostate. Breast. Lung. Colon. Each cancer type has a different biology, a different progression, and a different response profile. The ivermectin and mebendazole study is a start — but dose ranging, duration testing, and trials across a variety of cancer types are what's needed next. Science doesn't end with a promising result. It starts there.

Join the Fight: https://t.co/rvCeXmwbdp

Courtesy of Newsmax @NEWSMAX, Katrina Szish @KatrinaSzish, Bob Brooks @BobBrooks_NMX

#MedicalFreedom

[Foster Coulson @FosterCoulson]

@ashvinmelwani Holy Hannah, that must mean you’re only making a 4X ROAS on Meta?

[Peter A. McCullough, MD, MPH® @P_McCulloughMD]

Tick Bite? Only Way to Stop Lyme is Prophylaxis

CDC: Doxycycline for Lyme Disease Prophylaxis

Post‑exposure prophylaxis after a tick bite

Indication: High‑risk Ixodes tick bite (endemic area, attached ≥36 hours, removed ≤72 hours ago)
Adult dose: Doxycycline 200 mg orally once (Wellness Company Emergency Medical Kit) @twc_health https://t.co/t7xNB67ZMD